Table 3. Comparison of Common Adverse Events Associated With Therapeutic Options in Follicular Lymphoma .
Adverse event | Immunotherapy | CAR T-cell | BsAb | EZH2 inhibitor | PI3Ki | |||
---|---|---|---|---|---|---|---|---|
Rituximab | Obinutuzumab | Lenalidomide | Axi-cel | Tisa-cel | Mosunetuzumab | Tazemetostat | Copanlisib | |
Blood and lymphatic system disorders | ||||||||
Cytopenia | x | x | x | x | x | |||
Anemia | x | x | x | x | ||||
Lymphopenia | x | x | ||||||
Leukopenia | x | x | x | x | x | |||
Neutropenia | x | x | x | x | x | x | ||
Thrombocytopenia | x | x | x | x | x | |||
Febrile neutropenia | x | |||||||
Cardiac disorders | ||||||||
Arrhythmias | x | |||||||
Tachycardia | x | |||||||
Gastrointestinal disorders | ||||||||
Abdominal pain | x | |||||||
Nausea | x | x | x | x | ||||
Vomiting | x | |||||||
Diarrhea | x | x | x | x | ||||
Constipation | x | x | ||||||
Oral ulceration/stomatitis | ||||||||
General disorders and administration site conditions | ||||||||
IRR | x | x | ||||||
Pyrexia/fever | x | x | x | x | ||||
Chills | x | x | ||||||
Asthenia | x | |||||||
Fatigue | x | x | x | x | x | x | x | |
Immune system disorders | ||||||||
Cytokine release syndrome | x | x | x | |||||
Infections and infestations | ||||||||
Infection | x | x | x | |||||
Nasopharyngitis | ||||||||
URTI | x | x | x | |||||
Metabolism and nutrition disorders | ||||||||
Anorexia | ||||||||
Decreased appetite | x | |||||||
Weight loss | ||||||||
Hyperglycemia | x | |||||||
Musculoskeletal and connective tissue disorders | ||||||||
Musculoskeletal pain | x | x | x | x | ||||
Nervous system disorders | ||||||||
Dizziness | x | |||||||
Encephalopathy | x | |||||||
Headache | x | x | x | |||||
Peripheral neuropathy | ||||||||
Tremor | x | |||||||
Respiratory, thoracic, and mediastinal disorders | ||||||||
Cough | x | x | x | |||||
Dyspnea | ||||||||
Hypoxia | x | |||||||
Skin and subcutaneous tissue disorders | ||||||||
Alopecia | ||||||||
Rash | x | x | ||||||
Vascular disease | ||||||||
Hypertension | x | |||||||
Hypotension | x |
Note. axi-cel = axicabtagene ciloleucel; BsAb = bispecific antibody; CAR T-cell therapy = chimeric antigen receptor T-cell therapy; EZH2 = enhancer of zeste homolog 2; IRR = infusion-related reaction; PI3Ki = phosphoinositide 3 kinase inhibitor; tisa-cel = tisagenlecleucel; URTI = upper respiratory tract infection.